Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2024-05-15 Share Issue/Capital Cha…
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the successful completion of a capital raise, specifically an 'Offre Globale' (Global Offering) totaling 19.2 million euros, comprising a primary offering of new shares and a secondary offering of existing shares. It details the use of proceeds (R&D, clinical trials), the pricing, the resulting share capital structure, and commitments from existing shareholders. This clearly falls under the category of updates on company fundraising and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-05-15 French
Inside Information / News release on accounts, results
Capital/Financing Update Classification · 98% confidence The document is an announcement titled "MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros." It details the issuance and sale of new ordinary shares, the pricing (€8 per share), the use of proceeds (R&D, Phase 3 trial funding), and provides a breakdown of shareholder capital structure before and after the offering. This content directly relates to fundraising, capital structure changes, and the issuance of new securities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the AGM resolutions authorizing the offering, the primary focus is the completion and details of the capital raise itself, not the AGM materials (AGM-R) or a general regulatory filing (RNS).
2024-05-15 English
Informations privilégiées / Communiqué sur comptes, résultats
Capital/Financing Update Classification · 99% confidence The document is a press release announcing the launch of a capital increase ('augmentation de capital') by MaaT Pharma, involving the issuance of new ordinary shares to institutional investors (Offre Réservée) and retail investors (Offre PrimaryBid), alongside a secondary sale of existing shares. The key elements are the fundraising amount (€18 million), the share price (€8), the intended use of proceeds (R&D, clinical trials), and details about subscription commitments. This clearly falls under the category of company fundraising and capital structure changes. Comparing this to the definitions: - 10-K/IR: This is not a full annual or interim financial report. - ER: This is more detailed than a simple earnings release; it's a specific financing event. - CAP (Capital/Financing Update): This definition perfectly matches the content, which details a share offering to raise capital. - SHA (Share Issue/Capital Change): While it involves share issuance, CAP is more specific for the announcement of a fundraising operation itself. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (over 27k characters), indicating it is the primary announcement, not just a brief RPA.
2024-05-14 French
Inside Information / News release on accounts, results
Capital/Financing Update Classification · 99% confidence The document is a press release announcing the launch of a 'Global Offering' of new shares and a secondary sale of existing shares, totaling approximately 18 million Euros. It details the offering price (€8 per share), the use of proceeds (funding R&D, Phase 3 trials), subscription commitments from existing shareholders, and the mechanics of the offering (Reserved Offering and PrimaryBid Offering). This activity directly relates to fundraising, capital structure changes, and the issuance of new securities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). Since it is the announcement of the financing event itself, it is classified as CAP rather than a general Regulatory Filing (RNS).
2024-05-14 English
Inside Information / News release on accounts, results
Regulatory Filings Classification · 95% confidence The document is titled "MaaT Pharma Provides a Business Update and Highlights Key Milestones for 2024." It details clinical trial progress (ARES Phase 3, IASO Phase 1), scientific data presentations (EBMT 2024, AACR), corporate updates (management appointment, US supply batch production), and lists upcoming investor conferences. This content structure—a summary of recent operational and clinical achievements, future milestones, and financial outlook—is characteristic of a general business update or a press release announcing operational progress, rather than a formal regulatory filing like a 10-K, a comprehensive Interim Report (IR), or a specific announcement like a Dividend (DIV) or Director's Dealing (DIRS). Since it is a press release providing an update on business activities, clinical pipeline, and future expectations, it most closely aligns with an Earnings Release (ER) if it were tied to quarterly results, or a general Regulatory Filing (RNS) if no other category fits. Given that it is a comprehensive business update released outside of a standard quarterly earnings cycle (it mentions March 2024 results in passing but focuses on operational milestones), and it is not a short announcement pointing to a separate, attached report (ruling out RPA), the best fit among the provided options for a general, non-financial-statement-heavy operational update press release is often the general Regulatory Filings category (RNS) or, if it contains key financial highlights, ER. However, since it is a 'Business Update' and not explicitly an 'Earnings Release' (ER), and it covers a broad range of operational news, RNS serves as the most appropriate general category for non-standard press releases. Revisiting the definitions: ER is for the *initial announcement of periodical financial results (key highlights only)*. This document is a *business update* with clinical milestones, not primarily focused on the initial release of Q1/Q2/Q3 financial figures. Therefore, RNS (Regulatory Filings / miscellaneous announcements) is the most suitable fallback classification for this type of operational press release.
2024-05-07 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 95% confidence The document is a press release dated May 7, 2024, providing an update on the company's activities, pipeline progress (MaaT013, MaaT033, MaaT034), operational points, and expected value creation milestones for 2024. It summarizes recent data presentations (EBMT 2024), clinical trial updates (Phase 3 ARES, Phase 1 IASO), management changes, and financial outlook. This format, focusing on recent achievements and future guidance in a news release style, strongly indicates an Earnings Release (ER) or a general corporate update. Since it focuses heavily on operational and pipeline progress rather than just the summary financial figures typical of a pure ER, and it is not a full annual report (10-K) or a detailed interim report (IR), it fits best as an Earnings Release, which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were purely a mandatory disclosure. Given the comprehensive nature of the update covering multiple facets of the business and future expectations, ER is the most appropriate fit among the specific options, as these updates often accompany quarterly results announcements, even if the financial summary itself is brief or implied (the text mentions cash runway until Q3 2024). It is not a Report Publication Announcement (RPA) because it contains substantial new information, not just a notice that a report is available. FY 2024
2024-05-07 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.